This is a Sources Sought notice for a potential future R&D contract to support the Epilepsy Therapy Screening Program (ETSP) by performing preclinical pharmacological evaluations of new therapeutic agents. The work involves established workflows for drug-resistant epilepsy, disease prevention and modification assays, and pharmacokinetic studies, primarily using human-focused assays and in vivo tests. The anticipated period of performance includes a base period from January 1, 2027, to December 31, 2027, with the potential for multiple 12-month option periods. The contractor must have an AAALAC International accredited animal facility and maintain specific animal welfare assurances. The government expects the prime contractor to perform the preponderance of the work, with limited subcontracting allowed.